

Please amend claim 1 as follows:

1. (Twice amended) A method for [treating L-selectin mediated inflammation] inhibiting the binding of a native L-selectin to peripheral lymphoid tissue comprising [administering to a patient in need a therapeutically effective amount of
- a) ] contacting said L-selectin with an isolated, purified CD34 glycoprotein having the [endothelial] glycoform of native CD34 isolated from peripheral lymph nodes.

Please add the following claim:

- 28. The method of claim 1 wherein said CD34 is isolated and purified from peripheral lymph nodes.--

### Support for the Amendments

The amendments in claim 1 are supported at least at page 1, lines 39-45; page 3, lines 1-18; and Example 1. Since the amendments do not require new search or extensive consideration by the Examiner, rather are believed to bring the claims in a form ready for allowance or, at least, reduce the issues for appeal, their entry after final rejection is respectfully requested.

### The Rejections

1. Applicants were requested to update the status of the parent application on the first line of the specification, which was done in the foregoing amendment.